New hope for kidney disease: JADE101 trial launches

NCT ID NCT07541287

Recruiting now Disease control Sponsor: Jade Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study tests a new drug, JADE101, in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants must be on stable standard care and have a kidney biopsy confirming the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease glomerulonephritis IgA glomerulonephritis immune system disorder kidney disorder nephritis proteinuria urinary system disorder Urogenital Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGA NEPHROPATHY

Contacts and locations

Locations

Jade Clinical Site
RECRUITING

Chula Vista, California, 91910, United States
Jade Clinical Site
RECRUITING

Arvada, Colorado, 80002, United States
Jade Clinical Site
RECRUITING

Denver, Colorado, 80220, United States
Jade Clinical Site
RECRUITING

Orlando, Florida, 32806, United States
Jade Clinical Site
RECRUITING

Pembroke Pines, Florida, 33029, United States
Jade Clinical Site
RECRUITING

Houston, Texas, 77099, United States
Jade Clinical Site
RECRUITING

Christchurch, 8011, New Zealand
Jade Clinical Site
RECRUITING

Seoul, 03722, South Korea
Jade Clinical Site
RECRUITING

Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.